243 related articles for article (PubMed ID: 30229902)
1. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.
Zhang M; Cong Q; Zhang XY; Zhang MX; Lu YY; Xu CJ
J Cell Physiol; 2019 May; 234(5):6361-6370. PubMed ID: 30229902
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
3. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
5. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
6. Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma.
Lu H; Lu Y; Xie Y; Qiu S; Li X; Fan Z
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578313
[TBL] [Abstract][Full Text] [Related]
7. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer.
Zhao J; Tan W; Zhang L; Liu J; Shangguan M; Chen J; Zhao B; Peng Y; Cui M; Zhao S
Biochem Pharmacol; 2021 Aug; 190():114536. PubMed ID: 33794187
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
9. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
Woolbright BL; Choudhary D; Mikhalyuk A; Trammel C; Shanmugam S; Abbott E; Pilbeam CC; Taylor JA
Mol Cancer Ther; 2018 Sep; 17(9):2004-2012. PubMed ID: 29907593
[TBL] [Abstract][Full Text] [Related]
10. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
Qin S; Li Y; Cao X; Du J; Huang X
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
[TBL] [Abstract][Full Text] [Related]
11. PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma.
Kitamura S; Yamaguchi K; Murakami R; Furutake Y; Higasa K; Abiko K; Hamanishi J; Baba T; Matsumura N; Mandai M
Cancer Sci; 2021 Nov; 112(11):4627-4640. PubMed ID: 34464482
[TBL] [Abstract][Full Text] [Related]
12. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
Wu YH; Chang TH; Huang YF; Chen CC; Chou CY
Oncotarget; 2015 Sep; 6(27):23748-63. PubMed ID: 26087191
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Yang Z; Zhang SL; Hu X; Tam KY
Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
[TBL] [Abstract][Full Text] [Related]
14. p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer.
Han CY; Patten DA; Lee SG; Parks RJ; Chan DW; Harper ME; Tsang BK
Mol Carcinog; 2019 Nov; 58(11):2161-2174. PubMed ID: 31486135
[TBL] [Abstract][Full Text] [Related]
15. Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells.
Sun H; Wang H; Wang X; Aoki Y; Wang X; Yang Y; Cheng X; Wang Z; Wang X
Theranostics; 2020; 10(15):6928-6945. PubMed ID: 32550913
[No Abstract] [Full Text] [Related]
16. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
17. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
18. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
19. Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.
Granados ML; Hudson LG; Samudio-Ruiz SL
PLoS One; 2015; 10(9):e0136893. PubMed ID: 26351843
[TBL] [Abstract][Full Text] [Related]
20. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
